AKESO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.7 HKD | +0.52% |
|
+10.93% | +4.96% |
| Sales 2023 | 4.53B 625M 4.89B 50B | Sales 2024 * | 2.68B 370M 2.89B 29.6B | Capitalization | 39.03B 5.39B 42.17B 431B |
|---|---|---|---|---|---|
| Net income 2023 | 2.03B 280M 2.19B 22.4B | Net income 2024 * | -406M -56.03M -439M -4.49B | EV / Sales 2023 | 7.84 x |
| Net cash position 2023 * | 1.72B 237M 1.85B 18.95B | Net Debt 2024 * | 1.52B 210M 1.64B 16.78B | EV / Sales 2024 * | 15.1 x |
| P/E ratio 2023 |
17.4
x | P/E ratio 2024 * |
-90.6
x | Employees | 2,778 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.33% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.52% | ||
| 1 week | +10.93% | ||
| Current month | +4.39% | ||
| 1 month | +4.39% | ||
| 3 months | +16.37% | ||
| 6 months | +17.92% | ||
| Current year | +4.96% |
1 week
43.95
49.00
1 month
42.4050.50
Current year
37.9555.00
1 year
30.3055.00
3 years
11.5069.90
5 years
11.5069.90
10 years
11.5069.90
| Managers | Title | Age | Since |
|---|---|---|---|
Baiyong Li
FOU | Founder | 56 | 18/03/12 |
Peng Zhang
FOU | Founder | 48 | 18/03/12 |
Michelle Xia
CEO | Chief Executive Officer | 58 | 18/03/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bo Tan
BRD | Director/Board Member | 51 | 31/03/20 |
Zhongmin Wang
FOU | Founder | 55 | 18/03/12 |
Yan Xu
BRD | Director/Board Member | 60 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.57% | 4 M€ | -27.92% | ||
| 0.44% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 48.7 | +0.52% | 3,523,080 |
| 25/04/24 | 48.45 | +2.11% | 3,023,085 |
| 24/04/24 | 47.45 | +1.06% | 3,631,190 |
| 23/04/24 | 46.95 | +5.86% | 3,580,316 |
| 22/04/24 | 44.35 | +1.03% | 3,531,845 |
Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am
More quotes
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
Calendar
19/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
45.08
CNY
Average target price
55.44
CNY
Spread / Average Target
+22.97%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +4.96% | 5.39B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 9926 Stock
